Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Long-term outcomes in high-risk patients with chronic lymphocytic leukemia treated with targeted therapies in the real-world

View Full Paper
Ask AI
Bookmark
Share

Authors

ZKZuzana KubováDEDominika EcsiovaMŠMartin Šimkovič

Discussion

Loading...

Member takes

Overview

Real-world evidence shows targeted therapies improve progression free survival in high-risk CLL patients, implying benefits over conventional chemotherapy.

Key Points

  • Targeted therapies significantly enhance progression free survival rates for chronic lymphocytic leukemia patients with high-risk features.
  • The 3-year progression free survival rate was 62% for patients on ibrutinib, with a treatment discontinuation rate of 15%.
  • Analysis of real-world evidence included 294 CLL patients receiving targeted therapies like venetoclax and BTK inhibitors.
  • The use of targeted therapies correlates with substantial improvements compared to chemotherapy in high-risk patients with CLL.

Cite This Study

Kubová et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1b7https://doi.org/10.1182/blood-2025-3907
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world comparison of BTKi monotherapy and fixed-duration BTKi–Venetoclax for first line treatment of chronic lymphocytic leukemia patients without TP53 mutations or IGHV rearrangement2025
  2. 2Outcomes with a fixed duration combination of bruton tyrosine kinase inhibitors and venetoclax in chronic lymphocytic leukemia: A systematic review and meta-analysis2025
  3. 3Upfront continuous BTK inhibitor (BTKi) versus time-limited venetoclax-BTKi combinations in CLL across IGHV subgroups: Results of an indirect analysis2025
  4. 4Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia in second and subsequent lines of therapy: Real-world data fron hemato-oncology centers  of slovakia2025
  5. 5Real‑world effectiveness and patient-centered outcomes of fixed‑duration vs continuous first‑line therapy in chronic lymphocytic leukemia (CLL)2025